Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

9,002 public trials 1,838 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Recruiting

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

NCT05977673

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia Alessandria, IT, Italy
  • Divisione di Oncologia e dei Tumori immuto-correlati, Centro Di Riferimento Oncologico Di Aviano Aviano, Italy
  • Istituto di Ematologia L. e A. Seràgnoli, AOU Policlinico S. Orsola-Malpighi Bologna, Italy
  • SC Ematologia, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia Brescia, Italy
View Trial Details
Recruiting

Study on Plasmablastic Lymphoma Patients

NCT06781359

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati Aviano, PN, Italy
  • Ospedale C.e G. Mazzoni, U.O.C. di Ematologia Ascoli Piceno, Italy
  • ASST Spedali Civili di Brescia, Ematologia Brescia, Italy
  • A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo Cuneo, Italy
View all 23 locations
View Trial Details
Recruiting

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

NCT07630545

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +19 more
Locations
  • The Royal Adelaide Hospital Adelaide, Australia
  • Doherty Clinical Trials Melbourne, Australia
  • Monash Health, Kingston Centre Melbourne, Australia
  • Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon Lille, France
View all 18 locations
View Trial Details
Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +16 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Institute Denver, Colorado, United States
  • University of Miami Coral Gables, Florida, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
View all 37 locations
View Trial Details
Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 50 locations
View Trial Details
Recruiting

A Study of CTD402 in T-ALL/LBL Patients

NCT07070219

Conditions
Acute Lymphocytic Leukemia Refractory, Disease Attributes, Hematologic Diseases, +14 more
Locations
  • Stanford University Palo Alto, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Chicago Chicago, Illinois, United States
  • Mayo Clinic - Rochester Rochester, Minnesota, United States
View Trial Details
Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118

Conditions
B-cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt Lymphoma, DNA Virus Infections, +17 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site Tampa, Florida, United States
View all 82 locations
View Trial Details
Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069

Conditions
Hemic and Lymphatic Diseases, Histiocytosis, Histiocytosis, Langerhans-Cell, +6 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
View all 120 locations
View Trial Details

Related conditions